Relevare Pharmaceuticals™ is a specialty pharmaceutical company focused on the development of novel therapies to treat chronic and acute pain. Relevare Pharmaceuticals™’ exciting clinical-stage pipeline is comprised of innovative programs that combine or reposition drugs known to be active at CNS targets that modulate pain perception and transmission, and for which there is strong safety evidence in humans.
The lead development program encompasses the combined administration of two known, orally-available analgesic agents, flupirtine and opioids, for the treatment of neuropathic pain; a broad therapeutic area that encompasses numerous indications with significant unmet medical need. The cost efficient clinical development program is directed towards two key therapeutic applications:
- the adjunct administration of flupirtine in combination with opioids for (i) the treatment of moderate-to-severe cancer pain that is inadequately relieved by opioids and (ii) the treatment of painful HIV-sensory neuropathy; and
- a fixed dose combination (FDC) product targeted for the treatment of painful diabetic neuropathy.
Relevare Pharmaceuticals™ also possesses a highly innovative and attractive compound pipeline that includes an injectible ion channel modulator for the treatment of acute or chronic severe pain and orally available NK1 antagonist combination therapies for the treatment of inflammatory and neuropathic pain.